Neotropix began enrolling patients in a Phase II trial to assess the efficacy of the novel oncolytic virus, NTX-010, in patients with extensive stage small cell lung cancer (SCLC). NTX-010 has been shown to be highly selective for certain neuroendocrine tumor types including SCLC. The current study is designed to determine activity of a single dose of NTX-010 when used immediately after completion of standard first line therapy for SCLC as NTX-010 replicates within the tumor generating more d...